Author:
Egeler Mees D.,van Leeuwen Marieke,Fraterman Itske,van den Heuvel Noelle M.J.,Boekhout Annelies H.,Lai-Kwon Julia,Wilthagen Erica A.,Eriksson Hanna,Haanen John B.,Wilgenhof Sofie,Ascierto Paolo A.,van Akkooi Alexander C.J.,van de Poll-Franse Lonneke V.
Reference88 articles.
1. First-line advanced cutaneous melanoma treatments: where do we stand?;Abdulkarim;JMIR Cancer,2021
2. ACS. Targeted Therapy Side Effects. 2020.
3. Agency E.M. Pharmacovigilance Risk Assessment Committee (PRAC). 2014.
4. Allaire J., 2012. RStudio: Integrated Development Environment for R, Boston, MA , 770 (394), 165–171.
5. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade;Andrews;Nat. Med.,2021